Jorge M Blando

5PUBLICATIONS
95CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 17, 2026
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Ben Tran, Mark Voskoboynik, Sang-We Kim

|Apr 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Jérôme Fayette, Lisa Licitra, Kevin Harrington

|Sep 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Tina Cascone, Gozde Kar, Jonathan D Spicer

|May 04, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.

Martin H Voss, Arun A Azad, Aaron R Hansen

|Jun 20, 2020
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.

Sangeeta Goswami, Yulong Chen, Swetha Anandhan

Pageof 1

Frequent Collaborators

2 joint publications

Ikbel Achour

1 joint publications

Martin H Voss

1 joint publications

Arun A Azad

1 joint publications

Aaron R Hansen